Integra LifeSciences
IART
281 hedge funds and large institutions have $2.34B invested in Integra LifeSciences in 2024 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 107 increasing their positions, 97 reducing their positions, and 40 closing their positions.
70% more call options, than puts
Call options by funds: $773K | Put options by funds: $454K
10% more repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 97
5% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 40
1% less funds holding
Funds holding: 284 → 281 (-3)
1.82% less ownership
Funds ownership: 86.26% → 84.44% (-1.8%)
20% less capital invested
Capital invested by funds: $2.94B → $2.34B (-$595M)
100% less funds holding in top 10
Funds holding in top 10: 4 → 0 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$64.9M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
+$22.5M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$19.8M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$14.1M |
| 5 |
DM
Deerfield Management
New York
|
+$13.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ClearBridge Investments
New York
|
-$108M |
| 2 |
MAP
Madison Avenue Partners
New York
|
-$45.4M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$20.7M |
| 4 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$16M |
| 5 |
Neuberger Berman Group
New York
|
-$14.2M |
IART Hedge Fund Activity: Q1 2024 in Review
281 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q1 2024, worth a combined $2.34B — down 20% from $2.94B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of IART and 38 opened new positions — a net loss of 2 holders — while 97 trimmed existing stakes and 107 added.
The largest buyer was Capital Research Global Investors, adding an estimated $64.9M. The largest seller was ClearBridge Investments, exiting entirely with an estimated $108M sold.
- 281 institutional investors held Integra LifeSciences (IART) as of Q1 2024, down from 284 in Q4 2023.
- Funds reported $2.34B of Integra LifeSciences stock for Q1 2024, down 20% quarter-over-quarter.
- 38 funds opened new Integra LifeSciences positions in Q1 2024 and 40 closed out, a net change of -2 holders.
- The largest Integra LifeSciences buyer in Q1 2024 was Capital Research Global Investors, an estimated $64.9M added.
- The largest Integra LifeSciences seller in Q1 2024 was ClearBridge Investments, an estimated $108M sold.
Based on aggregated 13F filings for Q1 2024.